Clinical Trials Browser

Completed × Pancreatic Neoplasms × surufatinib × Clear all

NCT05481463 2025-05-28

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms